-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In September 2022, license-in and license-out transactions by local companies remained active
.
According to the global trading section of GBI SOURCE database, there are more than ten related transactions, most of which are License-in, mainly covering oncology, metabolism, nervous system and other fields
.
Table 1.
Licensing of the introduction transaction in September 2022
Licensing of the introduction transaction in September 2022
Source: GBI SOURCE Global Trading Sector
GBI SOURCE Table 1.
External licensing transactions in September 2022
External licensing transactions in September 2022
Source: GBI SOURCE Global Trading Sector
GBI SOURCELicense the introduction of transactions
License the introduction of transactionsLicense-in
Northeast Pharmaceutical introduced the MAb11-22.
1 antibody project of MedAbome Company for $15 million
1 antibody project of MedAbome Company for $15 million
■ Licensor: Meida Biotechnology Co.
, Ltd
■Licensee: Tohoku Pharmaceutical
Licensee: ■ Product/Technology: MAb11-22.
1
Northeast Pharmaceutical Group Co.
, Ltd.
and MedAbome of the United States reached an agreement
on the transfer, cooperative development and technical services of the MAb11-22.
1 antibody project.
MedAbome will transfer MAb11-22.
1 to Northeast Pharmaceutical and provide the proprietary technology required for the project; the two companies will collaborate on the development of antibody-conjugated drugs (ADCs) and CAR-T cell therapy products
based on this antibody.
Northeast Pharmaceutical has MAb11-22.
1 antibody and drugs based on the antibody in the United States, Canada, Mexico outside the three countries of the global patent rights, research and development rights, registration rights, production rights and commercialization rights
.
Party A has the right to transfer, and Party B cooperates; However, such transfer shall not affect Party B's rights and interests
in this Agreement.
At the same time, MedAbome will help and guide Northeast Pharmaceutical to design and build ADC platform and CAR-T cell therapy technology platform
.
Northeast Pharmaceutical paid MedAbome a down payment of US$6 million and RMB6 million, a milestone payment of US$7 million and RMB7 million after subsequent conditions, and a commission on net sales of new drugs for
the project.
Fosun Pharma acquired the rights and interests of Neovii anti-human T cell rabbit immunoglobulin Grafalon Greater China
Fosun Pharma acquired the rights and interests of Neovii anti-human T cell rabbit immunoglobulin Grafalon Greater China■ Licensor: Neovii Pharmaceuticals AG
Licensors:■Licensee: Fosun Pharma
Licensee:■ Product/Technology: Grafalon
Product/Technology: Shanghai Fosun Pharma (Group) Co.
, Ltd.
recently signed an exclusive sales agent and development agreement with Neovii Pharmaceuticals AG in Switzerland to obtain Neovii's authorization to exclusively sell and develop its immunosuppressant Grafalon (anti-human T-cell rabbit immunoglobulin injection) in China,
Hong Kong, Macao and Taiwan.
According to the agreement, Fosun Pharma will pay Neovii a sales agent royalty and a payment based on the listing milestone of the cooperative variety, and the two parties will settle the sales
price and sales commission.
In addition, Fosun Pharma may authorize its subsidiaries to commercialize
the cooperative varieties.
Star Cerrijin acquired the exclusive rights of corneal regeneration therapy from Cellusion Corporation of Japan
Star Cerrijin acquired the exclusive rights of corneal regeneration therapy from Cellusion Corporation of Japan ■ Licensor: Cellusion Inc.
■ Licensee: Star Sai Ruizhen
Licensee:■ Product/Technology: CLS001
Product/Technology: Hangzhou Xingsai Ruizhen Biotechnology Co.
, Ltd.
, a subsidiary of Fosun Pharma, entered into a licensing agreement with Cellusion
, a Japanese regenerative medicine company.
Under the agreement, Starcer will receive the rights
to develop, manufacture and commercialize CLS001, Cellusion's leading regenerative therapy candidate.
CLS001 is a corneal endothelial cell replacement derived from induced pluripotent stem cells (IPSCs), providing a new option
for human corneal transplantation alternatives.
Star Celeste will be granted the exclusive right
to develop CLS001 in Chinese mainland, Hong Kong, Macau and Taiwan for the treatment of large vesicular corneal lesions, the main cause of blindness requiring corneal transplantation.
Cellusion will receive payments in excess of $100 million, including upfront and milestone payments, as well as royalties
based on future sales.
Chemchemie has obtained an exclusive license for Voronoi's pan-RAF inhibitors
Chemchemie has obtained an exclusive license for Voronoi's pan-RAF inhibitors■ Licensor: Voronoi
Licensors:■Licensee: Yaktai Pharmaceutical
Licensee:■ Product/Technology: Type II pan-RAF kinase inhibitor
Product/Technology: Pharma Pharma announces an agreement
with Voronoi, Inc.
of South Korea.
Pharma will receive exclusive permission
to develop and commercialize Voronoi's pan-RAF inhibitor project worldwide.
Voronoi will receive up to $1.
7 million in cash for down payments, up to $480.
5 million in development, regulatory and sales milestone payments, and tiered royalties
based on annual net sales.
Otek Pharma will acquire exclusive rights to a type II pan-RAF kinase inhibitor developed by Voronoi, which is designed to target class II and III BRAF mutations
that the current generation of RAF inhibitors have not addressed.
Over $300 million! Chia Tai Tianqing introduces NASH medicine Lanilano Greater China interest
Over $300 million! Chia Tai Tianqing introduces NASH medicine Lanilano Greater China interest■ Licensor: Inventiva Pharma
Licensors:■ Licensee: Chia Tai Tianqing
Licensee:■ Product/Technology: Lanilano
Product/Technology: Chia Tai Tianqing, a Chinese biopharmaceutical subsidiary, has entered into a license agreement with French biotechnology company Inventiva S.
A.
to develop, manufacture and commercialize LaniLanifibranor
in Chinese mainland, Hong Kong, Macau, Taiwan (Greater China).
The product is Inventiva's core product for the treatment of non-alcoholic steatohepatitis and other potential metabolic disorders
.
Chia Tai Tianqing will pay Inventiva a $12 million down payment, $5 million in potential milestone payments, and $290 million in clinical, registration, and commercialization milestone payments (China Biopharma Announcement reports a $12 million down payment + $40 million in potential clinical and registration milestone payments
).
。 After the product is approved for marketing in Greater China, Chia Tai Tianqing will pay additional commercialization milestone payments and tiered commissions based on net sales in Greater China, and Inventiva will receive high single-digit to medium-double-digit royalties and low to mid-double-digit royalties
starting in the 4th year.
Hansen Pharmaceuticals received €66 million in KiOmed Osteoarthritis Drugs Chinese mainland, Macau and Taiwan
Hansen Pharmaceuticals received €66 million in KiOmed Osteoarthritis Drugs Chinese mainland, Macau and Taiwan■ Licensor: KiOmed Pharma
Licensors:■Licensee: Hansen Pharmaceuticals
Licensee:■ Product/Technology: KiOmedine One
Product/Technology: Hansen Pharmaceutical Group Co.
, Ltd.
announced that its wholly-owned subsidiaries, Hansen (Shanghai) Health Technology Co.
, Ltd.
, Jiangsu Haosen Pharmaceutical Group Co.
, Ltd.
and Jiangsu Hengte Pharmaceutical Sales Co.
, Ltd.
, have reached an agreement
with KiOmed Pharma SA.
Hansen Pharma obtained an exclusive license from KiOmed to develop and commercialize KiOmedine One for the treatment
of osteoarthritis in Chinese mainland, Macau and Taiwan.
Hansen Pharma will be responsible for the development, registration approval and commercialization of KiOmedine One and its future osteoarthritis expansion indications in the authorized area, and will pay advance payments and potential payments for development, registration and commercialization milestones based on sales totaling no more than €66 million, as well as double-digit graded royalties
based on future net sales of the product.
Zaiding Pharma acquired the exclusive rights and interests of Seagen cervical cancer ADC drug TIVDAK in Greater China
Zaiding Pharma acquired the exclusive rights and interests of Seagen cervical cancer ADC drug TIVDAK in Greater China ■ Licensor: Seagen INC.
■Licensee: Zai Ding Pharmaceutical
Licensee:■ Product/Technology: TIVDAK
Product/Technology: Zai Ting Pharma announced an exclusive partnership and licensing agreement
with Seagen Inc.
, a U.
S.
-based biotechnology company, for the development and commercialization of an antibody-conjugated drug (ADC) TIVDAK (tisotumab vedotin-tftv) in Chinese mainland, Hong Kong, Macau and Taiwan.
TIVDAK is the first and currently the only ADC
approved in the United States for the treatment of adults with recurrent or metastatic cervical cancer who develop disease progression during or after chemotherapy.
Under the terms of the agreement, Seagen will receive an advance payment of $30 million, plus development, registration and commercialization milestone payments, as well as TIVDAK's net sales tiered royalties
in Zai Ding Pharma's licensed area.
Merck granted Sinopharm Monoravir the right to distribute and import exclusively in China
Merck granted Sinopharm Monoravir the right to distribute and import exclusively in China■ Licensor: Merck
Licensors:■Licensee: Sinopharm Group
Licensee:■ Product/Technology: Monupiravir
Product/Technology: Merck announced the signing of a cooperation framework agreement
with Sinopharm.
Merck granted Sinopharm the distribution and exclusive import rights to molnupiravir, an oral anti-coronavirus drug developed in collaboration with Ridgeback, and the two sides will assess the feasibility of technology transfer for the production, supply and commercialization
of the drug in China.
Monoravir is an oral small molecule new crown virus treatment drug
.
Worldwide, Monoravir has obtained marketing or emergency use authorizations
in more than 40 countries or regions, including the United States, the European Union, Australia, Japan, South Korea, Hong Kong and Taiwan.
External licensing transactions
External licensing transactionsLicense-out
Merck is awarded a global license for Nerviano Medical Sciences PARP1 inhibitors
Merck is awarded a global license for Nerviano Medical Sciences PARP1 inhibitors ■ Licensor: Nerviano Medical Sciences S.
r.
l
■ Licensee: Merck
Licensee:■ Product/Technology: NMS-293
Product/Technology: Nerviano Medical Sciences, an Italian company invested by Haichen Pharmaceuticals, recently announced that it has entered into a cooperation and licensing agreement
with Merck Healthcare, a subsidiary of Merck Healthcare, Germany.
Under the agreement, Merck will be granted the rights
to develop and commercialize the polymerization (ADP-ribose) polymerase 1 (PARP1) inhibitor NMS-293 worldwide.
Merck will pay a $65 million upfront payment, as well as milestone payments and royalties
based on future sales.
In November 2017, Huaxi Shares, Haichen Pharmaceutical, Gaoyan Venture Capital, Eucalyptus Capital, etc.
announced that they jointly invested in the acquisition of 90% of the equity of Nerviano Medical Sciences, and in March 2018, the transaction was completed
.
Meitheal and HKF received US$6 million USD in Albumin Paclitaxel from Shuangcheng Pharmaceuticals
Meitheal and HKF received US$6 million USD in Albumin Paclitaxel from Shuangcheng Pharmaceuticals■ Licensor: Shuangcheng Pharmaceutical
Licensors: ■ Licensees: Meitheal Pharmaceuticals, Hong Kong King-Friend Industrial Co.
, Ltd.
■ Product/Technology: Paclitaxel, albumin
Product/Technology: Hainan Shuangcheng Pharmaceutical Co.
, Ltd.
announced the signing of licensing and supply agreements
with Meitheal Pharmaceuticals, Inc.
and Hong Kong King-Friend Industrial Co.
, Ltd.
Shuangcheng Pharmaceuticals granted Meitheal and HKF
an exclusive licensing interest in its injectable paclitaxel (albumin-conjugated, 100mg/bottle) in the United States.
Meitheal is responsible for the marketing planning and sales of injectable paclitaxel (albumin-conjugated) in the United States, and after the product is listed, Meitheal shall pay Shuangcheng Pharmaceutical for the profit share
generated by the sale of the product in the United States.
HKF is required to pay a certain one-time milestone payment to Shuangcheng Pharmaceutical, totaling US$6 million
.
Luye Pharmaceutical and ICI Pakistan have reached a distribution and promotion cooperation license in Pakistan
Luye Pharmaceutical and ICI Pakistan have reached a distribution and promotion cooperation license in Pakistan■ Licensor: Green Leaf Pharmaceutical
Licensors:■ Licensee: ICI Pakistan
Licensee:■ Product/Technology: SilkConnect
Product/Technology: According to reports, Luye Pharmaceutical Group has reached a cooperation with Pakistani company ICI Pakistan to grant its subsidiary Serikang (quetiapine fumarate, immediate-release) exclusive distribution and promotion rights
in the Pakistani market.
Stricon is used for the treatment of schizophrenia and bipolar disorder and is recommended by authoritative guidelines in many countries
.
*Log in to the global trading section of GBI SOURCE database to learn more
GBI SOURCE Global TransactionsOver $500 million! Simcere Pharma granted Almirall an interest in the autoimmune drug candidate SIM0278 outside Greater China
Over $500 million! Simcere Pharma granted Almirall an interest in the autoimmune drug candidate SIM0278 outside Greater China■ Licensor: Simcere Pharmaceuticals
Licensors: ■Licensee: Almirall S.
A.
■ Product/Technology: SIM0278
Product/Technology: Simcere Pharmaceuticals announces an exclusive licensing agreement
with Almirall S.
A.
Under the agreement, Almirall will acquire the exclusive rights
to develop and commercialize all indications outside Greater China for Simcere Pharmaceuticals' autoimmune drug candidate SIM0278.
Simcere Pharmaceuticals will receive a down payment of $15 million from Almirall and up to $492 million in development and commercial milestone payments based on possible outcomes for multiple indications, including partial sales milestones, and a low double-digit percentage tiered commission
based on future sales of the product in the agreed territories.